Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats
International Journal of Immunopathology and Pharmacology · 2023
DOI: 10.1177/03946320231161469 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Abdallah Salah El-Din Hussein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Objectives
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder. The proportion of elderly individuals at risk for AD and cardiovascular problems increases by raising life expectancy. The present study was designed to investigate the effect of the sacubitril/valsartan combination compared to that of valsartan alone in a rat model of AD.
Methods
72 male adult Wistar rats were divided into seven groups; control untreated rats received saline, control valsartan-treated rats received valsartan orally, control sacubitril/valsartan treated rats received sacubitril/valsartan orally, model rats received aluminum chloride i.p., model valsartan treated rats received aluminum chloride i.p. and valsartan orally and model sacubitril/valsartan treated rats received aluminum chloride i.p. and sacubitril/valsartan combination orally. All previous treatments continued on a daily basis for 6 weeks. At the second, fourth, and sixth weeks of the experiment, behavioral changes were evaluated using the Morris water maze and novel object recognition tests, and systolic blood pressure was measured. In the end, rat brain malondialdehyde and amyloid-beta 1-42 levels were measured, and the isolated hippocampus was evaluated histopathologically.
Results
Valsartan improved AD symptoms in the aluminum-induced rat model, while the sacubitril/valsartan combination significantly worsened all tested parameters in both control and model rats compared with untreated and valsartan-treated animals.
Conclusion
Based on the current study’s findings, valsartan did not increase the risk for AD development in control rats and improved AD symptoms in a rat model, while sacubitril/valsartan combination increased the risk of AD in control rats and worsened the condition in a rat model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Histology, Faculty of Medicine, Cairo University, Cairo, Egypt.
ORCID-Profile: Afaf S Osman
Zitieren
APA
El-Din Hussein, A. S., Abou-El Nour, R. K. E., Khorshid, O. A., & Osman, A. S. (2023). Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231161469
Vancouver
El-Din Hussein AS, Abou-El Nour RKE, Khorshid OA, Osman AS. Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231161469
BibTeX
@article{ElDinHussein2023,
author = {El-Din Hussein, Abdallah Salah and Abou-El Nour, Rahma Kamal El-Din and Khorshid, Omayma A and Osman, Afaf S},
title = {Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer’s disease model in rats},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2023},
doi = {10.1177/03946320231161469}
}
EUVIMED